Immediate zoledronic acid treatment better than delayed in women receiving letrozole
the ONA take:
Immediate treatment with zoledronic acid prevented bone loss compared with delayed treatment in postmenopausal women receiving letrozole for breast cancer and these differences were maintained at 5 years, a study published in the American Cancer Society journal Cancer has found.
Because it is known that postmenopausal women with breast cancer receiving aromatase inhibitors are at a higher risk for bone loss, researchers sought to compare the impact of immediate versus delayed treatment with zoledronic acid on bone loss.
Researchers analyzed data from 551 postmenopausal women who had received tamoxifen and were now receiving daily letrozole. Patients were randomly assigned 1:1 to upfront or delayed zoledronic acid 4mg IV every 6 months.
Results showed that the incidence of a 5% decrease in the total lumbar spine bone density was 10.2% and 41.2% in the upfront and delayed groups, respectively (P < 0.0001), suggesting that immediate treatment prevented bone loss moreso than delayed treatment at 5 years; however, researchers found that the incidence of osteoporosis or fractures was not significantly different between treatment arms.
Immediate treatment with zoledronic acid prevented bone loss compared with delayed treatment in breast cancer.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered
- The Bounty of Failure: A Well-Versed Nursing Experience
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|